Switch theme
Sign up to access all valuation multiples
Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.
1978
9.9K+
LTM Revenue $3.1B
LTM EBITDA $869M
$20.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sartorius Stedim Biotech has a last 12-month revenue of $3.1B and a last 12-month EBITDA of $869M.
In the most recent fiscal year, Sartorius Stedim Biotech achieved revenue of $3.0B and an EBITDA of $720M.
Sartorius Stedim Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sartorius Stedim Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.0B | $3.0B | XXX | XXX | XXX |
| Gross Profit | $2.0B | $1.3B | XXX | XXX | XXX |
| Gross Margin | 66% | 44% | XXX | XXX | XXX |
| EBITDA | $812M | $720M | XXX | XXX | XXX |
| EBITDA Margin | 27% | 24% | XXX | XXX | XXX |
| Net Profit | $941M | $333M | XXX | XXX | XXX |
| Net Margin | 32% | 11% | XXX | XXX | XXX |
| Net Debt | $986M | $3.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sartorius Stedim Biotech's stock price is EUR 170 (or $183).
Sartorius Stedim Biotech has current market cap of EUR 16.5B (or $17.8B), and EV of EUR 18.7B (or $20.1B).
See Sartorius Stedim Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.1B | $17.8B | XXX | XXX | XXX | XXX | $3.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sartorius Stedim Biotech has market cap of $17.8B and EV of $20.1B.
Sartorius Stedim Biotech's trades at 6.6x LTM EV/Revenue multiple, and 23.1x LTM EBITDA.
Analysts estimate Sartorius Stedim Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sartorius Stedim Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $20.1B | XXX | XXX | XXX |
| EV/Revenue | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | 27.9x | XXX | XXX | XXX |
| P/E | 94.5x | XXX | XXX | XXX |
| P/E/Growth | 1.5x | XXX | XXX | XXX |
| EV/FCF | 39.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSartorius Stedim Biotech's NTM/LTM revenue growth is 9%
Sartorius Stedim Biotech's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Sartorius Stedim Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sartorius Stedim Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sartorius Stedim Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 33% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 29% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sartorius Stedim Biotech acquired XXX companies to date.
Last acquisition by Sartorius Stedim Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Sartorius Stedim Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sartorius Stedim Biotech founded? | Sartorius Stedim Biotech was founded in 1978. |
| Where is Sartorius Stedim Biotech headquartered? | Sartorius Stedim Biotech is headquartered in France. |
| How many employees does Sartorius Stedim Biotech have? | As of today, Sartorius Stedim Biotech has 9.9K+ employees. |
| Who is the CEO of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's CEO is Dr. Rene Faber, PhD. |
| Is Sartorius Stedim Biotech publicy listed? | Yes, Sartorius Stedim Biotech is a public company listed on PAR. |
| What is the stock symbol of Sartorius Stedim Biotech? | Sartorius Stedim Biotech trades under DIM ticker. |
| When did Sartorius Stedim Biotech go public? | Sartorius Stedim Biotech went public in 1994. |
| Who are competitors of Sartorius Stedim Biotech? | Similar companies to Sartorius Stedim Biotech include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's current market cap is $17.8B |
| What is the current revenue of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's last 12-month revenue is $3.1B. |
| What is the current EBITDA of Sartorius Stedim Biotech? | Sartorius Stedim Biotech's last 12-month EBITDA is $869M. |
| What is the current EV/Revenue multiple of Sartorius Stedim Biotech? | Current revenue multiple of Sartorius Stedim Biotech is 6.6x. |
| What is the current EV/EBITDA multiple of Sartorius Stedim Biotech? | Current EBITDA multiple of Sartorius Stedim Biotech is 23.1x. |
| What is the current revenue growth of Sartorius Stedim Biotech? | Sartorius Stedim Biotech revenue growth between 2023 and 2024 was 0%. |
| Is Sartorius Stedim Biotech profitable? | Yes, Sartorius Stedim Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
